Restricted accessLetterFirst published online 2011-07
The Roche Elecsys and Siemens-Centaur Thyroglobulin Autoantibody Assays Show Comparable Clinical Performance to the Recently Unavailable Beckman-Coulter Access Thyroglobulin Autoantibody Assay in Identifying Samples with Potentially False-Low Thyroglobulin Measurements Due to Thyroglobulin Autoantibody Interference
GrebeSKG. 2009. Diagnosis and management of thyroid carcinoma: a focus on serum thyroglobulin. Expert Rev Endocrinol Metab, 4:25–43.
2.
SpencerCA, BergoglioLM, KazarosyanM, FatemiS, LoPrestiJS. 2005. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab, 90:5566–5575.
3.
La'uluSL, SlevPR, RobertsWL. 2007. Performance characteristics of 5 automated thyroglobulin autoantibody and thyroid peroxidase autoantibody assays. Clin Chimica Acta, 376:88–95.
4.
SpencerC, PetrovicI, FatemiS. 2011. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab, 96:1283–1291.
